24 January, 2020
Skadden advised I-MAB, a Chinese biotechnology company, on its US$104 million initial public offering of ADS on Nasdaq. Shanghai-based I-MAB is developing drugs to treat cancers and autoimmune disorders. Trading commenced on 17 January 2020.
The team was led by Hong Kong partner Julie Gao and Shanghai partner Haiping Li, with counsel Yuting Wu (Shanghai), associates Ming Kong and Lu Ma (both Hong Kong), and international legal consultant Xiaoxi Gong (Shanghai).
